CAPR Quote, Financials, Valuation and Earnings

Inovio Pharmaceuticals has a net margin of -63.94% compared to Capricor Therapeutics's net margin of -30140.49%. Capricor Therapeutics's return on equity of -75.99% beat Inovio Pharmaceuticals's return on equity of -125.47%.

Capricor Therapeutics has a consensus price target of $42.13, signalling upside risk potential of 257.6%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $8.00 which suggests that it could grow by 300%. Given that Inovio Pharmaceuticals has higher upside potential than Capricor Therapeutics, analysts believe Inovio Pharmaceuticals is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 0.842, which suggesting that the stock is 15.842% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.344, suggesting its more volatile than the S&P 500 by 34.39%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Capricor Therapeutics's net income of -$24.4M is lower than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 20.52x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals has a net margin of -63.94% compared to Capricor Therapeutics's net margin of -2004.36%. Capricor Therapeutics's return on equity of -75.99% beat Lexicon Pharmaceuticals's return on equity of -90.8%.

Capricor Therapeutics has a consensus price target of $42.13, signalling upside risk potential of 257.6%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $2.58 which suggests that it could grow by 284.21%. Given that Lexicon Pharmaceuticals has higher upside potential than Capricor Therapeutics, analysts believe Lexicon Pharmaceuticals is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 0.842, which suggesting that the stock is 15.842% less volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.318%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.3M. Capricor Therapeutics's net income of -$24.4M is higher than Lexicon Pharmaceuticals's net income of -$25.3M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 20.52x versus 7.51x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Neurocrine Biosciences has a net margin of -63.94% compared to Capricor Therapeutics's net margin of 1.38%. Capricor Therapeutics's return on equity of -75.99% beat Neurocrine Biosciences's return on equity of 12%.

Capricor Therapeutics has a consensus price target of $42.13, signalling upside risk potential of 257.6%. On the other hand Neurocrine Biosciences has an analysts' consensus of $159.40 which suggests that it could grow by 28.14%. Given that Capricor Therapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Capricor Therapeutics is more attractive than Neurocrine Biosciences.

Capricor Therapeutics has a beta of 0.842, which suggesting that the stock is 15.842% less volatile than S&P 500. In comparison Neurocrine Biosciences has a beta of 0.239, suggesting its less volatile than the S&P 500 by 76.136%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Neurocrine Biosciences pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are smaller than Neurocrine Biosciences quarterly revenues of $572.6M. Capricor Therapeutics's net income of -$24.4M is lower than Neurocrine Biosciences's net income of $7.9M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Neurocrine Biosciences's PE ratio is 42.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 20.52x versus 5.33x for Neurocrine Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Vaxart has a net margin of -63.94% compared to Capricor Therapeutics's net margin of -74.68%. Capricor Therapeutics's return on equity of -75.99% beat Vaxart's return on equity of -94.14%.

Capricor Therapeutics has a consensus price target of $42.13, signalling upside risk potential of 257.6%. On the other hand Vaxart has an analysts' consensus of $4.67 which suggests that it could grow by 564.77%. Given that Vaxart has higher upside potential than Capricor Therapeutics, analysts believe Vaxart is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 0.842, which suggesting that the stock is 15.842% less volatile than S&P 500. In comparison Vaxart has a beta of 1.255, suggesting its more volatile than the S&P 500 by 25.549%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vaxart offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Vaxart pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are smaller than Vaxart quarterly revenues of $20.9M. Capricor Therapeutics's net income of -$24.4M is lower than Vaxart's net income of -$15.6M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Vaxart's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 20.52x versus 3.21x for Vaxart. Usually stocks with elevated PS ratios are considered overvalued.